Media.Player

Novel Group A Streptococcal Vaccine and Therapeutics

詳細技術說明

Scientists at UC San Diego have developed novel genetic GAS mutants expressing GAC without the GlcNAc side chain. This invention is the use of the A-variant carbohydrate purified from the mutant as a vaccine, which will induce anti-GAC antibodies that would be protective against all serotypes of GAS. The mutant GAC may also be used as a vaccine strategy against other medically important pathogens including groups C and G Streptococcus (GCS, GGS).

*Abstract

Group A streptococcus (GAS) is a ubiquitous human pathogen behind a spectrum of diseases. Worldwide, invasive S. pyogenes infections result in excess of half a million deaths each year. To date, there has been no effective GAS vaccine developed in part because there are more than 150 serotypes. A diagnostic for GAS has been developed utilizing the carbohydrate structure of the GAS called Group A carbohydrate (GAC) consisting of a rhamnose backbone and an immunodominant N-acetylglucosamine (GlcNAc) side chain. Initially, utilizing this same structure as a potential vaccine produced good outcomes in animals but safety concerns were raised since antibodies generated against the GlcNAc side chain could precipitate other conditions (e.g. rheumatic carditis and Sydenham's chorea).

*IP Issue Date

Jul 13, 2017

*Principal Investigation

Name: Victor Nizet

Department:

Name: Nina Van Sorge

Department:

主要類別

生物醫學

細分類別

病原

申請號碼

20170196962

其他

Related Materials

• van Sorge, N.M. et al. 2011. Streptococcus Pyogenes Group A Carbohydrate as Virulence Factor and Vaccine Candidate. Microbial Pathogenesis and Host Response Symposium, Cold Spring Harbor, New York.
• Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular Insight Into Invasive Group A Streptococcal Disease. Nat Rev Microbiol. 2011 Sep 16;9(10):724-36.

Tech ID/UC Case

22219/2012-011-0

Related Cases

2012-011-0

國家/地區

美國